BioVentures, LLC

Disclosed herein is deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure. Use of deuterated buprenorphine prevents or reduces exposure of the fetus to opioids used by the mother. Use of deuterated buprenorphine may prevent or reduces exposure of the fetus to harmful metabolites of buprenorphine.

A photoacoustic flow cytometry (PAFC) device for the in vivo detection of cells circulating in blood or lymphatic vessels is described. Ultrasound transducers attached to the skin of an organism detect the photoacoustic ultrasound waves emitted by target objects in response to their illumination by at least one pulse of laser energy delivered using at least one wavelength. The wavelengths of the laser light pulse may be varied to optimize the absorption of the laser energy by the target object. Target objects detected by the device may be unlabelled biological cells or cell products, contrast agents, or biological cells labeled with one or more contrast agents.

A device and method of using the device to detect the presence and composition of clots and other target objects in a circulatory vessel of a living subject is described. In particular, devices and methods of detecting the presence and composition of clots and other target objects in a circulatory vessel of a living subject using in vivo photoacoustic flow cytometry techniques is described.

Disclosed herein are systems and methods for personalized AI-guided motion-gated coronary CTA scanning. The method may include receiving initial CT data from a CT scanner, generating a four-dimensional (4D) computed tomography (CT) image of the heart of the patient from the initial CT data, identifying mechanical movement of the heart of the patient and an initial timeframe when the myocardium of the heart of the patient is in a target position, and using the mechanical movement of the heart of the patient and the initial timeframe to predict a subsequent timeframe when the heart of the patient will be in the target position. The system may include at least one processor and a memory storing instructions that, when executed by the at least one processor, causes the at least one processor to perform any or all of the method steps, operations, or processes described in the present disclosure.

The disclosure provides a method of preventing or reducing protein aggregates using combretastatin-A4 (CA4) or an analog thereof. The disclosure also provides methods of reducing the risk, delaying the onset, delaying or slowing the progression, or reversing the signs or symptoms of a neurodegenerative (or other age-progressive) disease using a combretastatin-A4 (CA4) or an analog thereof. The combretastatin-A4 (CA4) or an analog thereof may bind glial fibrillary acidic protein (GFAP). The combretastatin-A4 (CA4) or an analog thereof is described by compounds of Formula (I).

The present disclosure encompasses methods for molecularly subtyping formalin-fixed paraffin-embedded tumor samples. The disclosure works particularly well for old and degraded (archival) samples for which standard methods are unfeasible. Further, the methods disclosed allow for the correlation of patient outcome data with the molecular subtype of the tumor and provides a wealth of information which will guide treatment decisions and/or selection of therapeutic agents.

Tocol derivative compounds, compositions comprising these tocol derivatives and methods of using the tocol derivatives are provided herein. Specifically the tocol derivatives have a partially unsaturated hydrocarbon tail and are thus distinct from the tocopherols. The hydrocarbon tails do not have a trans carbon-carbon double bond in the second isoprene unit of the hydrocarbon tail and are distinct from the tocotrienols. The compounds are expected to allow improved interaction with the α-tocopherol transfer protein receptor than the tocotrienols and better bioactivity than the tocopherols.

The present disclosure pertains to a stent that includes a proximal end and a distal end; and a plurality of interconnected and expandable rings positioned adjacent to one another from the proximal end to the distal end. Each ring is connected to and spaced apart from at least one adjacent ring through one or more connecting units. Additionally, the interconnected rings form a cavity. The rings at or near the proximal end include different diameters than the rings at or near the distal end. The present disclosure also pertains to methods of implanting a stent of the present disclosure in a blood vessel of a subject through the following steps: (1) positioning the stent at a desired location within the blood vessel; and (2) expanding the stent from a contracted configuration to an expanded configuration to secure the stent to the blood vessel wall.

Disclosed herein are RNA methyltransferase inhibitors and methods of using and making the same. The inhibitors may be used in a method for the treatment of a subject in need of a treatment for a cancer by administering an effective amount of the RNA methyltransferase inhibitor and an effective amount of a DNA damaging agent to the subject.

Disclosed herein are devices and systems for analyzing one or more conditions of a patient. The system may comprise a device comprising a tubular body having a first lumen operable to deliver a fluid, at least one sensor at near tip of the tubular body, configured to measure a peripheral venous pressure within a vein of the patient, and at least one processor configured to receive a peripheral venous pressure (PVP) waveform from the at least one sensor, process the PVP waveform, and determine one or more conditions of the patient based on the processed PVP waveform.